Runping Su
Impact in
- Pharmaceutical Science top 10%
- Advancements in Transdermal Drug Delivery
-
- Immunotherapy and Immune Responses
- Immune cells in cancer
Papers in
-
- Immunotherapy and Immune Responses 5
-
- Cancer Research and Treatments 3
- Co-authors
- Yongyong Li (7 shared papers)Jie Zang (6 shared papers)Haiqing Dong (6 shared papers)Yue Wang (1 shared paper)Yu Qin Guo (1 shared paper)Xiangqun Jin (1 shared paper)Yang Li (1 shared paper)Shanshan Yu (1 shared paper)
- Journals
- Chemical Engineering Journal (2 papers)Journal of Nanobiotechnology (2 papers)Nature Metabolism (1 paper)ACS Biomaterials Science & Engineering (1 paper)ACS Nano (1 paper)
- Partner nations
- ChinaAustraliaUnited States
In The Last Decade
Runping Su
16 papers receiving 312 citations
Peers
Comparison fields: 5 of 64
- Pharmaceutical Science 30
- Immunology 79
- Biomaterials 47
- Dermatology 24
- Biotechnology 21
Countries citing papers authored by Runping Su
This map shows the geographic impact of Runping Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Runping Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Runping Su more than expected).
Fields of papers citing papers by Runping Su
This network shows the impact of papers produced by Runping Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Runping Su. The network helps show where Runping Su may publish in the future.
Co-authors
The 25 scholars most cited alongside Runping Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 71 | |
| 2 | 2020 | 50 | |
| 3 | 2024 | 40 | |
| 4 | 2021 | 30 | |
| 5 | 2022 | 24 | |
| 6 | 2022 | 19 | |
| 7 | 2022 | 18 | |
| 8 | 2022 | 13 | |
| 9 | 2024 | 13 | |
| 10 | 2020 | 12 | |
| 11 | 2023 | 12 | |
| 12 | 2025 | 7 | |
| 13 | 2023 | 4 | |
| 14 | 2026 | 2 | |
| 15 | 2024 | 2 | |
| 16 | 2026 | 1 | |
| 17 | 2025 | 0 | |
| 18 | 2025 | 0 |
About Runping Su
Runping Su is a scholar working on Immunology, Biotechnology, Pharmaceutical Science, Biomedical Engineering and Molecular Biology, having authored 18 papers that have together received 318 indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (6 papers), Immunotherapy and Immune Responses (5 papers), Cancer Research and Treatments (3 papers), Bacteriophages and microbial interactions (3 papers), RNA Interference and Gene Delivery (3 papers), Nanoparticle-Based Drug Delivery (2 papers), Virus-based gene therapy research (2 papers) and Gut microbiota and health (2 papers). The work is most often cited by research in Pharmaceutical Science (30 citations), Immunology (79 citations), Biomaterials (47 citations), Dermatology (24 citations) and Biotechnology (21 citations). Runping Su has collaborated with scholars based in China, Australia and United States. Frequent co-authors include Yongyong Li, Jie Zang, Haiqing Dong, Yue Wang, Yu Qin Guo, Xiangqun Jin, Yang Li, Shanshan Yu, Qianqian Zhao and Yi Han. Their work appears in journals such as Chemical Engineering Journal, Journal of Nanobiotechnology, Nature Metabolism, ACS Biomaterials Science & Engineering and ACS Nano.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.